We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Metabolon partners with InnVentis to Study Chronic Inflammatory Diseases

News   Jan 06, 2017 | Metabolon

 
Metabolon partners with InnVentis to Study Chronic Inflammatory Diseases
 
 
 

RELATED ARTICLES

Evidence Reinforcing Approval of New Cancer Drugs Raises Questions

News

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, according to a new study.

READ MORE

Making Chemotherapy More Effective Against Pancreatic Cancer

News

Using patient cell lines and tumor-bearing models, researchers have discovered that inhibition of GSK-3, an enzyme involved in many cancer-promoting processes, sensitizes pancreatic cancer cell lines to gemcitabine, the most commonly used chemotherapy.

READ MORE

Senescent Cell Burden Is Reduced in Humans by Senolytic Drugs

News

In a small safety and feasibility clinical trial, Mayo Clinic researchers have demonstrated for the first time that senescent cells can be removed from the body using drugs termed “senolytics”.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE